Novo Nordisk Lifts 2026 Guidance on Wegovy Sales Surge

Novo Nordisk Lifts 2026 Guidance on Wegovy Sales Surge

Danish pharmaceutical giant Novo Nordisk has raised its full-year 2026 guidance, driven by surging sales of its GLP-1 weight-loss drug Wegovy. The company now expects adjusted sales and profit to contract between 4% and 12%, an improvement from previous forecasts. This revision comes on the back of strong first-quarter results, where sales jumped 32% on a constant currency basis to reach 96.8 billion Danish kroner ($15.2 billion) on a reported basis. According to CNBC, Novo's Wegovy brand now commands 65% of all new prescriptions in the U.S., a milestone CEO Mike Doustdar described as a 'turnaround situation.'

Key Takeaways

1. Novo Nordisk raised its 2026 guidance as GLP-1 product sales, led by Wegovy, outperformed expectations.
2. Wegovy now holds a 65% share of new U.S. prescriptions, signaling strong market dominance.
3. Meanwhile, Danish jeweler Pandora faces headwinds from U.S. import tariffs and rising silver prices, impacting margins.

The positive outlook for Novo Nordisk contrasts with challenges faced by another Danish company, Pandora. The jewelry maker has been under pressure from the Trump administration's import tariffs and a surge in the price of silver, which have weighed on its margins. As reported by CNBC, these factors have negatively impacted Pandora's financial performance, highlighting the divergent fortunes of Denmark's corporate giants.

Novo Nordisk's strong performance underscores the growing demand for GLP-1 drugs, which are used for weight loss and diabetes management. The company's upward revision of its 2026 guidance reflects confidence in continued growth, despite potential market headwinds. Wegovy's increasing market share in the U.S. is a key driver, as it captures a larger portion of new prescriptions. The CEO's characterization of the situation as a 'turnaround' suggests that the company has successfully navigated earlier challenges and is now poised for sustained expansion.

In contrast, Pandora's struggles highlight the impact of geopolitical and commodity price risks on businesses. The combination of tariffs and higher silver costs has squeezed margins, forcing the company to reassess its strategies. These developments come amid broader market uncertainties, including trade tensions and fluctuating raw material prices.

Overall, the news from Denmark presents a mixed picture: one of pharma-driven optimism and jewelry-sector caution. Investors will be watching closely to see how these trends evolve in the coming months.